Having trouble viewing this email? View in your browser.

12 January 2021

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.


ECCMID 2021 Abstract submission is now open!

Abstract submission for the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) is now open!

Visit the ECCMID Abstract Website to view the abstract guidelines and to submit your work for inclusion in the world’s premier meeting in the field of infection.

Be sure to watch the Abstract Submission Tutorial before starting your submission.

Abstracts will be accepted until the deadline on 24 February 2021 at 15:59 CET.

› Read more

New ECCMID Grant: 21 for ’21!

As ECCMID moves to a hybrid format, with options for online participation, ESCMID is pleased to announce another grant initiative, where 21 full access online tickets will be granted to abstract presenters that cannot make it to Vienna to present their abstract.

Find out more and apply on the ECCMID Awards and Grants page.

› Read more

Call for panel members of ESCMID clinical practice guidelines on COVID-19 – Extended by 24 hours

ESCMID is launching a new initiative to develop ESCMID guidelines on several COVID-19 related issues.
The guidelines will issue clinical recommendations for diagnosis and treatment of adult patients with suspected and confirmed COVID-19:

  1. diagnosis (including differential diagnosis) (including diagnosis of reinfection)
  2. optimal setting for management (home or community management, medical ward, semi-intensive ward, intensive care unit)
  3. drug treatment and clinical management of patients with COVID-19
  4. post-discharge and long-term follow-up
  5. prevention and efficacy of individual protection measures to reduce infection

ESCMID is therefore currently seeking candidates willing to serve on the panel(s) of these projects.
The deadline to submit your application is January 13th 2021 at 12:00 CET.

Please visit our website for more information on how to apply. 

› Read more

Via ECDC: New tender - Genomic-based Surveillance of Carbapenem-resistant Acinetobacter baumannii at the European level.

ECDC has released a new online tender with the title ‘Genomic-based Surveillance of Carbapenem-resistant Acinetobacter baumannii at the European level’.

A detailed description of the tender and links to the submission portal are available on the ECDC website.

The deadline to apply is 10 February, 2021.

› Read more

EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca

EMA has received an application for conditional marketing authorisation (CMA) for a COVID-19 vaccine developed by AstraZeneca and Oxford University. The assessment of the vaccine, known as COVID-19 Vaccine AstraZeneca, will proceed under an accelerated timeline. An opinion on the marketing authorisation could be issued by 29 January during the meeting of EMA’s scientific committee for human medicines (CHMP), provided that the data submitted on the quality, safety and efficacy of the vaccine are sufficiently robust and complete and that any additional information required to complete the assessment is promptly submitted.

The press release has been published here.

You can also check EMA’s dedicated webpage on COVID-19 for the latest updates.

› Read more

GARDP Live Webinar: Manipulating the host response to treat infections

Don’t miss the next GARDP Live Webinar, which will take place live on Thursday, 14 January 2021 from 17:00-18:30 CET.

Join R.E.W. (Bob) Hancock (University of British Columbia, Canada) and Henk P. Haagsman (Utrecht University, Netherlands) will discuss ways in which host responses can be manipulated to treat infections.

The discussion will be moderated by Neeloffer Mookherjee (University of Manitoba, Canada).

› Read more

ESCMID-SFM Manual of Microbiology

Looking for an excellent and affordable Clinical Microbiology desk reference?

The ESCMID-SFM Manual of Clinical Microbiology is available at a great discount!
This essential guide for all microbiologists is only 25 EUR including shipping!

Order your copy online now!

› Read more

CMI highlight: The importance of anosmia, ageusia and age in community presentation of symptomatic and asymptomatic SARS-CoV-2 infection in Louisiana, USA; a cross-sectional prevalence study

This investigation focused on defining the nature and frequency of symptomatic and asymptomatic SARS-CoV-2 infection in a representative, cross-sectional sample of communities in Louisiana, USA.

By using representative sampling, a survey of symptoms, and antibody testing with paired PCR, we were able to determine the prevalence of symptomatic and asymptomatic SARS-CoV-2 infection infections in the community. This study found that around 47% of infections were asymptomatic, almost 30% of positive cases reported anosmia/ageusia, and those who reported anosmia/ageusia had higher odds of testing positive versus any other symptomatic group.

Anosmia/ageusia seems to be a hallmark of COVID-19 even in the cluster of symptoms that represents low or no symptoms and can be used therefore to differentiate SARS-CoV-2 infection from other illnesses. Regular testing in congregant settings of those over age 60 may help mitigate asymptomatic spread

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Phone +41 61 5080 173
Visit us on LinkedIn Visit us on YouTube
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.